Kyverna Therapeutics Inc (KYTX) saw an uptrend of 1.64% in the recent trading with $1.86 being its most recent. The current price level -91.71% lower than the highest price of $22.44 marked by the stock while trading over the past 52-weeks, whereas it is 3.91% higher than the lowest price of $1.79 the company dropped to over past 52-weeks. The latest news story on KYTX appeared in (GlobeNewswire) under the title “Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) – Grabar Law Office Is Investigating Claims on Your Behalf”.
Squeezing the time span to 30 day period shows us the stock is currently trading -27.63% below one month high and is +4.49% above of the lowest during that time. Looking into the simple moving average, Kyverna Therapeutics Inc (KYTX)’s stock stands at a SMA-50 of $2.4660 while that of 5-day is reading $1.9930.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and KYTX’s SMA-200 as of now is $4.9756.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.33 for the stock.
Kyverna Therapeutics Inc Earnings – What Happened With KYTX
Coming around sales and income figures on KYTX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
KYTX – Kyverna Therapeutics Inc Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 43.21 million. KYTX does have institutional investors; and they hold 32.69% of the stock.
Kyverna Therapeutics Inc – Insider Activity and Holdings
As on 2024-06-30, VIDA VENTURES ADVISORS, LLC was the top most holder in Kyverna Therapeutics Inc (NASDAQ:KYTX) with an ownership of 4.52 million shares of the company or 10.4901 of the stake worth $33.93 million. The filing also reveals BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC as the second largest holder in the company with a control over 7.8106 of the outstanding shares. Its stake is worth $25.26 million for having 3.37 million shares in hand.
NORTHPOND VENTURES, LLC also came holding a key position in the company during the recent quarter and it now holds 7.5487 of the outstanding shares. With this there are now 127.0 institutions which have possession in KYTX’s shares.
Currently, the stock has been recommended as Strong Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.33 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Kyverna Therapeutics Inc has a debt to equity ratio of 0.03.
Technical Analysis of Kyverna Therapeutics Inc (NASDAQ:KYTX) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Kyverna Therapeutics Inc (KYTX), we notice that the stock’s 20-day average volume is at 298,700 shares and 100% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 100% are spotting the stock at Sell with its 50-day average volume of 292,530 shares. And to end, KYTX’s 100-day average volume is 353,626 shares with 100% of the long-term indicators pointing towards Sell for the stock.
